Christopher Ryan Sullivan - 13 Aug 2024 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
13 Aug 2024
Net transactions value
$0
Form type
4
Filing time
14 Aug 2024, 16:11:10 UTC
Previous filing
13 Jun 2023
Next filing
30 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AVTX Common Stock 6 13 Aug 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +186,700 $0.000000 186,700 13 Aug 2024 Common Stock 186,700 $9.88 Direct F1
transaction AVTX Restricted Stock Units Award $0 +72,600 $0.000000 72,600 13 Aug 2024 Common Stock 72,600 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock upon the vesting date.
F3 The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

Remarks:

The amount of beneficial securities owned in Table I has been adjusted to reflect a 1-for-240 reverse stock split on December 28, 2023.